The Impact of Epigenetic MMRd in Endometrial carcinomas-a Real World Study

NCT05334303UNKNOWNOBSERVATIONAL

Summary

Key Facts

Lead Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Enrollment

400

Start Date

2022-11-17

Completion Date

2024-05-01

Study Type

OBSERVATIONAL

Official Title

Prevalence and Prognostic Impact of Epigenetic MMRd in Endometrial Carcinomas

Conditions

Endometrial Neoplasms

Eligibility

Sex

FEMALE

Inclusion Criteria:

* all patients diagnosed with endometrial cancer in our hospital from 2019 to 2022

Exclusion Criteria:

* those without histological specimens in our hospital

Outcome Measures

Primary Outcomes

Proportion of MMRd caused by MLH1 promoter methylation in endometrial carcinoma

the prevalence of epigenetic MMRd in endometrial cancer

Time frame: up to two years

Secondary Outcomes

progression-free survival time (PFS)

progression-free survival time (PFS)

Time frame: up to two years

The Impact of Epigenetic MMRd in Endometrial carcinomas-a Real World Study